Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 12NIH 7OTHER 6NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 45Vincristine 37Cisplatin 31Radiotherapy 30Radiation 30Carboplatin 29Dexamethasone 28Etoposide 26Biopsy 26Doxorubicin 24daratumumab 18Prednisone 18Radiotherapy, Intensity-Modulated 17durvalumab 16Platinum 16Irinotecan 16Cytarabine 16Paclitaxel 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Methotrexate 14Leucovorin 14Docetaxel 14Observation 13Lenalidomide 13Radiotherapy, Conformal 12Fluorouracil 12Calcium Dobesilate 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Crizotinib × 1 year × Clear all
NCT03297606 2026-03-27

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting
720 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
166 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡